ABL-specific tyrosine kinase inhibitor, ST1571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis [2]

Leukemia

Volumn 15, Issue 6, 2001, Pages 989-990

  Nakajima, A ^a   Tauchi, T ^a   Ohyashiki, K ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; APOPTOSIS; BLAST CELL CRISIS; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE INACTIVATION; GENETIC ENGINEERING; GENETIC STABILITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; INCUBATION TIME; INFORMED CONSENT; KARYOTYPE; LETTER; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION;

EID: 0034988035     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402137     Document Type: Letter

References (7)

1. BCR-ABL signal transduction
2. A BCR-ABL kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges
3. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of BCR-ABL positive cells
4. In vivo eradication of human BCR-ABL-positive leukemia cells with an ABL kinase inhibitor
5. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor ST1571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
6. Trial of IFN or ST1571 before proceeding to allografting for CML?
7. Vitamin K2 induces apotosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation